subacute, late subacute, and chronic.
Nontraumatic Subarachnoid Hemorrhage
Nontraumatic subarachnoid hemorrhage is typically related to
an aneurysm (75%) or a vascular malformation, such as an
arteriovenous malformation or cavernous angioma.
Nonaneurysmal "perimesencephalic" subarachnoid
Dural sinus or cerebral vein occlusion is rare, representing <
1% of strokes. Venous thrombosis risk factors include
pregnancy, trauma, dehydration, infection, oral
contraceptives, coagulopathies, malignancies, collagen
vascular diseases, and protein C and S deficiencies. Venous
infarcts occur in only ~ 50% of venous thrombosis cases and
can be differentiated from arterial infarcts by the location of
the ischemia. Superior sagittal sinus thrombosis typically
results in T2/FLAIR hyperintense parasagittal lesions, whereas
thrombosis of the transverse sinus often results in T2/FLAIR
hyperintensities in the posterior temporal lobe. Additionally,
venous infarcts more commonly present with associated
hemorrhage. CECT is useful to identify the "empty delta" sign
representing nonenhancing thrombus within a major dural
sinus, typically the superior sagittal or transverse sinus.
Cerebral ischemia results from significantly decreased blood
flow to selected areas or the entire brain. Stroke progresses in
stages from ischemia to actual infarction. In the most common
situation, MCA occlusion, there is a densely ischemic central
core and a less densely ischemic "penumbra." The central core
is usually irreversibly damaged unless reperfusion is quickly
established, whereas the cells within the penumbra may
remain viable but at risk for several hours. Current stroke
therapies attempt to rescue the "at-risk" cells.
Currently, acute stroke protocols vary among different
institutions. The exact protocol is often based on the
availability of CT vs. MR, technology/software, time of stroke,
physician expertise, and the possibility of neurointervention.
Typically, stroke neurologists work with neuroradiologists to
devise a plan that best serves the patient's needs.
Most stroke protocols begin with a noncontrast head CT to
evaluate for hemorrhage or mass, which directly affects
treatment decisions. Additionally, > 1/3 of MCA territory
hypodensity at presentation is considered by most to be a
contraindication to thrombolysis, as it is associated with a
greater risk of fatal hemorrhage. CTA is useful to evaluate for
large-vessel occlusion. When available, CT perfusion is an
excellent way to evaluate for large=vessel ischemia.
MR with DWI is particularly useful for acute ischemia when CT
perfusion is negative and the clinical suspicion for stroke
remains. MR is also the primary imaging tool when the clinical
question includes a posterior fossa or brainstem lesion. MR
with PWI has been found extremely helpful in guiding therapy
Most stroke protocols use 3-hour and 6-hour windows for
treatment of nonhemorrhagic ischemic stroke. If the patient
presents within 6 hours after the initial onset of symptoms, an
unenhanced CT is typically the initial study of choice to
exclude a mass or hemorrhage. If there is a hemorrhage or
mass, no thrombolytic therapy is initiated. If there is no
hemorrhage or mass and the patient is within 3 hours after
onset of symptoms, the patient is eligible for intravenous (IV)
thrombolysis. If the patient is between 3 and 6 hours of onset,
either a CTA with CT perfusion or an MR with DWI and PWI is
performed to determine whether they are eligible for
treatment. If the patient has an intracranial thrombus with a
penumbra, intraarterial (IA) thrombolysis or IA thrombectomy
is recommended. If there is no penumbra, IA therapy may not
benefit the patient, so each case is evaluated individually.
No comments:
Post a Comment
اكتب تعليق حول الموضوع